PharmaEssentia provided updates on its 2024 financial performance, 2025 outlook, and the ongoing commercial arbitration with AOP during its latest investor conference. The company’s legal team anticipates a prolonged arbitration process, estimating that a final ruling will not be reached in 2025. While the case continues, PharmaEssentia has not ruled out the possibility of exploring mediation options.
Fueled by the continued global sales growth of its innovative polycythemia vera (PV) treatment, Ropeginterferon alfa-2b (Ropeg), PharmaEssentia achieved a record-breaking financial year in 2024. The company reported:
In terms of regional revenue distribution, the Americas accounted for 78%, followed by Asia (12%) and Europe (10%). Notably, PharmaEssentia achieved near double revenue growth with only a modest 40-person increase in its global workforce, while keeping expense growth at just 6%, significantly improving profitability and operational efficiency.
The company’s fourth-quarter results continued the upward trajectory, achieving:
Given these trends, PharmaEssentia anticipates sustained sequential revenue growth in 2025, with a focus on maximizing profitability through sales expansion and cost control. To reward shareholders, the board has approved its first-ever dividend distribution of NT$1.1 per share in cash and NT$1.1 per share in stock.
The recent global shortage of Pegasys (pegylated interferon alfa-2a) has heightened industry attention. Originally developed and marketed by Roche, Pegasys was acquired by Austria-based Pharma& in 2021, but supply chain disruptions led to widespread shortages across the U.S., Europe, Canada, and Brazil. The U.S. FDA officially announced Pegasys’ discontinuation on January 24, 2025, with supply expected to resume only by May 31, 2026.
With Ropeg already established as an advanced interferon therapy, PharmaEssentia is well-positioned to capture additional market share during this supply gap.
PharmaEssentia is advancing the global Phase 3 clinical trial for Ropeg’s use in treating essential thrombocythemia (ET). Key trial results demonstrated significant long-term efficacy over the control group, with a P-value of 0.0001, confirming strong statistical significance.
The company plans to present these findings at the American Society of Clinical Oncology (ASCO) and the European Hematology Association (EHA) annual meetings. Regulatory submissions for ET approval will be filed in multiple markets, including the U.S., Japan, and China, with targeted approvals by 2026. PharmaEssentia is actively preparing commercialization strategies to establish ET as its next major growth driver.
On February 17, 2024, PharmaEssentia received a partial final award from the International Chamber of Commerce (ICC) arbitration panel. Unlike an earlier arbitration ruling, which had previously ordered PharmaEssentia to pay NT$4.8 billion (later overturned by the German Federal Supreme Court due to insufficient evidence from AOP), the latest ruling only requires a payment of €1.56 million (approximately NT$54 million) plus interest.
Key takeaways from the arbitration ruling:
The tribunal is expected to convene discussions in March or April 2025 to outline the next steps. PharmaEssentia’s legal team anticipates a protracted process, making it unlikely to conclude within 2025. As the arbitration continues, the company remains committed to evaluating legal strategies and may consider mediation as a potential resolution path.
Despite ongoing legal proceedings, PharmaEssentia’s core business remains on a strong growth trajectory. With expanding Ropeg sales, an upcoming ET indication, and effective cost control, the company is positioned for sustained profitability. The recent dividend approval and favorable arbitration developments further reinforce confidence in its long-term stability and shareholder value creation.
Resource: 藥華藥: 與AOP仲裁今年不會終結 不排除尋調解途徑
